Skip to content

Prospective Research in Infants With Mild Encephalopathy

Prospective Research in Infants With Mild Encephalopathy: the PRIME Study.

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01747863
Acronym
PRIME
Enrollment
63
Registered
2012-12-12
Start date
2012-12-31
Completion date
2017-06-30
Last updated
2025-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brain Injury, Hypoxic-Ischemic Encephalopathy, Neonatal Seizure

Keywords

Hypoxic Ischemic encephalopathy

Brief summary

A multicenter observational pilot study will be conducted to determine the natural history of infants with early diagnosis (≤ 6 hrs of age) of mild neonatal encephalopathy (NE) who are not qualified for therapeutic hypothermia. The intervention includes: neurologic examination by using modified Sarnat score at ≤ 6 hrs of age, 24 hrs and before discharge home, amplitude-integrated electroencephalography (aEEG) at 6 ± 3 hrs of age, brain MRI at before discharge home to 30 days of age and follow-up at 18-22 months of age. Primary outcome is the percentage of mild NE infants with evidence of brain injury defined by the presence of at least 1 abnormality of brain MRI, aEEG or neurologic examination in the neonatal period. Secondary outcome is the percentage of brain MRI, aEEG and neurological exam abnormalities, seizure, length of hospital stay, need of gavage feeds or gastrostomy at discharge home, death and long-term outcome.

Detailed description

Globally, an estimated 1.8 to 7.7 infants per 1000 live term births suffer from perinatal asphyxia, which remains an important cause of neonatal encephalopathy (NE) and neurodevelopmental impairment. Over the last six years, several randomized control trials have demonstrated that prolonged and moderate therapeutic hypothermia (TH) reduces the rate of death or disability at 18 months of age among infants who survived. In these trials, infants were eligible if there was evidence of perinatal hypoxia-ischemia and a moderate or severe degree of encephalopathy on neurological evaluation performed at ≤ 6 hrs of age. However, it has been recognized that the level of NE may change over time. Preliminary and unpublished observations from our group indicated that some infants who were not classified as moderate or severe NE had neurological abnormalities at discharge or evidence of brain injury on MRI performed during the neonatal period. Unfortunately, precise data on the outcomes of this specific population is not clear. Since TH is not offered to this population, the outcomes of infants that do not qualify for TH based on neurological evaluation performed ≤ 6 hrs of life requires a more precise investigation.

Interventions

Neurologic examination includes: (1) neurologic examination using modify Sarnat score at \</= 6 hrs of age, 24 hrs and at discharge home, (2) aEEG at 6 ± 3 hrs of age, (3) Brain MRI before discharge home to 30 days of age.

Sponsors

Brown University
CollaboratorOTHER
University of Texas Southwestern Medical Center
CollaboratorOTHER
Wayne State University
CollaboratorOTHER
Mahidol University
CollaboratorOTHER
Ohio State University
CollaboratorOTHER
Imperial College London
CollaboratorOTHER
McGill University Health Centre/Research Institute of the McGill University Health Centre
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
No minimum to 6 Hours
Healthy volunteers
No

Inclusion criteria

* Infants with birth weight \> or = 1800g and gestational age \> or = 36 weeks AND * Admission to neonatal intensive care unit (NICU) for possible hypothermia at \< or = 6hr of life

Exclusion criteria

* Infants with normal neurological evaluation * Major congenital abnormalities * Refusal of informed consent * Infants who receive passive or active cooling prior to the NICU admission * Infants that develop seizures or moderate/severe NE within the first 24 hr of life and are initiated on therapeutic hypothermia after 6 hr of life.

Design outcomes

Primary

MeasureTime frameDescription
Percentage of Infants With Evidence of Neurological Dysfunction, Brain Injury and/or Abnormality.1 monthEvidence of neurological dysfunction/injury/abnormality will be defined by any of these 3 criteria, as follows: 1. MRI = Brain MRI score of pattern of injury (NICHD-NRN) \> 0, 2. aEEG = abnormal background pattern on aEEG (voltage or background pattern) at 6 ± 3 hrs of age. 3. Any abnormality on the neurological at discharge exam.

Secondary

MeasureTime frameDescription
Percentage of Infants With SeizuresParticipants will be followed for the duration of hospital stay, an expected average of 3 daysDevelopment of clinical or electrographic seizures
Length of Hospital StayParticipants will be followed for the duration of hospital stay, an expected average of 3 days
Percentage of Infants Who Need Gavage Feeds or Gastrostomy at Discharge HomeParticipants will be followed for the duration of hospital stay, an expected average of 3 days
Mortality RateParticipants will be followed for the duration of hospital stay, an expected average of 3 daysDeath during the hospitalization

Other

MeasureTime frameDescription
Long-term Neurodevelopment18-22 months of ageLong-term outcomes (18-22 months of age): Severe disability if there is a Bayley III Cognitive score \< 70, severe cerebral palsy (CP), defined by the Gross Motor Function Classification System (GMFCS) grade level 3 to 5, blindness or profound hearing loss. Moderate disability will be defined as the Bayley Cognitive score is 70-84 and either seizures, moderate CP (defined by GMFCS grade level 2) or a hearing deficit requiring amplification to understand commands. Mild disability will be defined by a cognitive score 70-84, or a cognitive score ≥ 85 and either presence of mild or moderate CP (GMFCS grade levels 1 or 2), a seizure disorder or hearing loss with or without amplification. Normal will be defined as Bayley III Cognitive score ≥ 85 without any visual or hearing impairment, or CP.

Countries

Canada, Thailand, United Kingdom, United States

Participant flow

Participants by arm

ArmCount
Mild NE
Infants with evidence of a perinatal event and NE who do not qualify for therapeutic hypothermia. Neurologic examination: Neurologic examination includes: (1) neurologic examination using modify Sarnat score at \</= 6 hrs of age, 24 hrs and at discharge home, (2) aEEG at 6 ± 3 hrs of age, (3) Brain MRI before discharge home to 30 days of age.
54
Total54

Baseline characteristics

CharacteristicMild NE
Age, Categorical
<=18 years
54 Participants
Age, Categorical
>=65 years
0 Participants
Age, Categorical
Between 18 and 65 years
0 Participants
Age, Continuous39.4 Gestational age(weeks)
STANDARD_DEVIATION 1.4
Race and Ethnicity Not Collected— Participants
Sex: Female, Male
Female
22 Participants
Sex: Female, Male
Male
32 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
— / —
other
Total, other adverse events
0 / 63
serious
Total, serious adverse events
0 / 63

Outcome results

Primary

Percentage of Infants With Evidence of Neurological Dysfunction, Brain Injury and/or Abnormality.

Evidence of neurological dysfunction/injury/abnormality will be defined by any of these 3 criteria, as follows: 1. MRI = Brain MRI score of pattern of injury (NICHD-NRN) \> 0, 2. aEEG = abnormal background pattern on aEEG (voltage or background pattern) at 6 ± 3 hrs of age. 3. Any abnormality on the neurological at discharge exam.

Time frame: 1 month

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Mild NEPercentage of Infants With Evidence of Neurological Dysfunction, Brain Injury and/or Abnormality.28 Participants
Secondary

Length of Hospital Stay

Time frame: Participants will be followed for the duration of hospital stay, an expected average of 3 days

Secondary

Mortality Rate

Death during the hospitalization

Time frame: Participants will be followed for the duration of hospital stay, an expected average of 3 days

Secondary

Percentage of Infants Who Need Gavage Feeds or Gastrostomy at Discharge Home

Time frame: Participants will be followed for the duration of hospital stay, an expected average of 3 days

Secondary

Percentage of Infants With Seizures

Development of clinical or electrographic seizures

Time frame: Participants will be followed for the duration of hospital stay, an expected average of 3 days

Other Pre-specified

Long-term Neurodevelopment

Long-term outcomes (18-22 months of age): Severe disability if there is a Bayley III Cognitive score \< 70, severe cerebral palsy (CP), defined by the Gross Motor Function Classification System (GMFCS) grade level 3 to 5, blindness or profound hearing loss. Moderate disability will be defined as the Bayley Cognitive score is 70-84 and either seizures, moderate CP (defined by GMFCS grade level 2) or a hearing deficit requiring amplification to understand commands. Mild disability will be defined by a cognitive score 70-84, or a cognitive score ≥ 85 and either presence of mild or moderate CP (GMFCS grade levels 1 or 2), a seizure disorder or hearing loss with or without amplification. Normal will be defined as Bayley III Cognitive score ≥ 85 without any visual or hearing impairment, or CP.

Time frame: 18-22 months of age

Source: ClinicalTrials.gov · Data processed: Mar 2, 2026